ProtAffin is a biotechnology company developing a novel class of biopharmaceuticals based on glycan-binding decoy proteins

 

ProtAffin has developed the CellJammer^® discovery technology to generate biopharmaceuticals addressing many of the highest priority disease targets in the pharmaceutical industry. Using this technology, the Company has created a pipeline of glycan-binding decoy proteins that cause potent down-regulation of protein function and have applications in inflammation, respiratory and oncology.
 
By developing biopharmaceuticals which bind glycans, ProtAffin avoids many limitations of established drug modalities, such as monoclonal antibodies and small molecules. The approach is applicable to over 900 targets contained in our proprietary database, including chemokines and growth factors.
 
ProtAffin’s lead product is PA401, an anti-inflammatory protein derived from interleukin-8 (IL-8) which was generated using CellJammer^® discovery technology. PA401 has shown outstanding preclinical efficacy in models of neutrophilic lung inflammation including COPD and is currently in a Phase 1 clinical study, which started in Q2 2012. COPD is the 4th leading cause of death in the western world.  PA401 has an excellent safety profile and superior efficacy versus competitors on the market and other products currently in development for the treatment of COPD.


In 2012 ProtAffin won EuropaBio's award for "Most Innovative EU Biotech SME". EuropaBio, the European Association for Bioindustries,  represents over 1800 companies and for further information on this award please see our press release and award presentation.